Cognito Therapeutics has reported outcomes from a post hoc analysis of its OVERTURE feasibility trial, indicating that the investigational Spectris AD therapy can slow the progression of Alzheimer’s disease.
The device utilises non-invasive neuromodulation with synchronised light and sound at a gamma frequency to restore disrupted brain activity in Alzheimer’s patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study involved 76 mild-to-moderate affected subjects. It included a randomised six-month controlled phase and a subsequent 12-month open-label extension.
During the controlled phase, one-hour treatments with the device daily led to 4.83 months of preserved daily activity, 4.56 and 4.09 months of delayed cognitive decline and whole-brain atrophy, respectively.
Subjects who received the device’s treatment showed a delay in progression of the disease compared to those in the sham treatment group.
Specifically, subjects initially assigned to Spectris AD and later treated with SPECTRIS in the open-label extension study showed a slower progression to the same degree of decline that the sham group experienced during six months.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTailored for at-home use, Spectris AD has been granted breakthrough device designation by the US Food and Drug Administration (FDA) and is now under assessment in the HOPE pivotal trial.
Cognito Therapeutics CEO Christian Howell said: “Our brains are electrical systems, and Alzheimer’s disrupts the rhythms that govern memory, cognition, and our ability to function.
“Spectris AD represents a new class of therapy, one based in physics, that restores these natural neural oscillations without relying on a chemistry-based pharmacologic therapy. These findings show the potential to meaningfully slow disease progression by leveraging the potential of neuromodulation.”
Last year, Cognito enrolled the first subject in a biomarker substudy within the HOPE trial evaluating the sensory stimulation device in Alzheimer’s patients.
